Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Arch Biopartners Inc. (V:ARCH)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 27 St. Clair Ave E.,
P.O. Box 305
TORONTO ON M4T 2M5
Tel: 1-647-4287031
Website: https://archbiopartners.com
IR: See website
Key People
Richard Muruve
President, Chief Executive Officer, Director
Andrew Bishop
Chief Financial Officer, Director
Daniel Muruve
Chief Science Officer
Business Overview
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.
Financial Overview
For the three months ended 31 December 2023, Arch Biopartners Inc revenues decreased 31% to C$298K. Net loss decreased 64% to C$783K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Share based compensation decrease of 70% to C$580K (expense), Research decrease of 70% to C$136K (expense), Insurance decrease of 48% to C$7K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $142.25M as of Dec 31, 2023
Annual revenue (TTM): $1.85M as of Dec 31, 2023
EBITDA (TTM): -$1.56M as of Dec 31, 2023
Net annual income (TTM): -$1.95M as of Dec 31, 2023
Free cash flow (TTM): -$0.48M as of Dec 31, 2023
Net Debt Last Fiscal Year: $4.73M as of Dec 31, 2023
Shares outstanding: 62,755,633 as of Dec 31, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization